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Abstract-Various neuroactive substances, including excitatory and inhibitory amino acids, biogenic 
amines and neuropeptides, were tested for their ability to stimulate the inositol phosphate (IPs) cascade 
in the presence of lithium in the rat cochlea. Among them, only the muscarinic agonists (carbachol and 
oxotremorine M) were able to stimulate the IPs formation in 12-day-old rat cochleas. The carbachol- 
elicited IPs formation was inhibited by muscarinic antagonists with the following relative order of 
potency: atropine > 4-DAMP apirenzepine > methoctramine = AF-DX 116. This pharmacological 
profile suggests that the activation of the M3 muscarinic receptor subtype is responsible for the increase 
in IPs synthesis in the rat cochlea. However, an interaction with a m5 receptor subtype could not be 
completely excluded. The unusual link of only one receptor subtype with the phosphoinositide breakdown 
in the cochlea, as opposed to the usual existence of several receptors coupled to this transduction system 
in other organs such as the brain, suggest a unique role for muscarinic agonists in the cochlea. 
The mammalian cochlea contains two types of hair 
cells: namely the inner hair cells (IHCs$) and the 
outer hair cells (OHCs). The auditory transmission 
between IHCs and the first auditory neurons (type I 
afferent neurons) is thought to be assumed by an 
excitatory amino acid, likely glutamate [l-4]. This 
transmission may be modulated by the efferent 
lateral olivocochlear fibers which synapse at the 
afferent dendrites of the type I auditory neurons. 
Several neurotransmitters including dopamine, 
GABA, acetylcholine have been identified in these 
fibers [5]. The OHCs receive neuronal information 
via the medial efferent system which is mainly chol- 
inergic [6]. In addition, the OHCs contact the den- 
drites of type II neurones, which represent the other 
afferent system of the cochlea. This afferent system, 
for which the neurotransmitter remains unknown, 
represents only 5% of the whole cochlear afferent 
system. 
The OHCs have been postulated to indirectly 
modulate IHCs activity [7,8] probably due to their 
motile properties. Motility (shortening and elong- 
ation) of isolated OHCs has been shown to occur in 
response to intracellular current administration (fast 
motility) [9] or in response to neuroactive substances 
such as potassium or acetylcholine (slow motility) 
[9, lo]. The molecular mechanisms, which underlie 
such OHCs motility, may originate from phos- 
phoinositide metabolism and the subsequent intra- 
cellular calcium mobilization [ll, 121, which in turn 
* To whom correspondence should be addressed. 
$ Abbreviations: IHC, inner hair cell; OHC, outer hair 
cell; CDAMF’, 4-diphenylacetoxy-N-methyl pipexidine 
methiodide; AF-DX 116, ll-((2-((diethylamino)-methyl)- 
l-piperidinyl)acetyl) - 5,ll - dihydro - 6H - pyrido(2,3 - b)- 
(1,4)-benzodiazepine-6 one. 
controls actin polymerization and the formation of 
microfilament assemblies [ 131. 
Despite the importance of such molecular mech- 
anisms in the understanding of cochlear functioning, 
no direct measurement of inositol phosphate for- 
mation has been performed in this organ. In the 
present paper, we examine the accumulation elicited 
by neuroactive substances of these second messenger 
molecules (inositol mono-, bis- and tris-phosphate) 
in the rat cochlea. 
MATERIALS AND METHODS 
Incorporation of[3H]inositol. Wistar rats of age 12 
days were killed by decapitation. After dissecting 
out the bony capsule, whole cochleas were rapidly 
removed and immediately placed in Krebs-Ringer 
buffer, pH 7.4. The Krebs-Ringer buffer used con- 
tained 125 mM NaCl; 3.5 mM KCl; 1.25 mM 
KH,PO,; 1.2 mM MgSO,; 1.5 mM CaCl*; 10 mM 
glucose and 25 mM NaHC03. Before use, this buffer 
was equilibrated to pH7.4 by saturation with a 
gaseous mixture of 95% 02 and 5% CO* (v/v). Myo- 
[2-3H]Inositol incorporation in 75 cochleas was car- 
ried out at 37”, under gassing of 95% 0,/5% CO*, 
for 75 min in 5 mL Krebs-Ringer buffer containing 
1 mM cytidine and 50 @i of the radioactive inositol 
(sp. act. 17Ci/mmol, CEA Saclay, France). The 
labelled cochleas were then washed four times in 
5 mL Krebs-Ringer buffer before being individually 
distributed in plastic tubes containing 500 PL Krebs- 
Ringer buffer. The tubes were then transferred to a 
water bath maintained at 37” and continuously gassed 
with the gaseous mixture of 95% OJS% CO* 
throughout the subsequent experimental steps. 
Agonist stimulation. LiCl (lOpL, final concen- 
tration 10mM) and 2OpL of an appropriate con- 
centration of an antagonist (where applicable) were 
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added to each tube. After 15 min, the stimulatory 
neuroactive substance or buffer (20 pL) was added. 
Following an additional 20min of incubation, the 
reaction was stopped by the addition of 5OpL per- 
chloric acid (PCA 72%) and, by placing the tubes 
on ice. 
Measurement of [3H]inositol phosphates. The 
labelled IPs were purified and measured according 
to the method described by Bone et al. [ 141 modified 
as follows: the cochleas were homogenized using an 
Ultraturrax homogenizer. The homogenates con- 
taining the PCA-extracted [3H]IPs were then centri- 
fuged at 2000g for 20 min. The resulting 
supernatants were poured off and retained while the 
pellets were resuspended by homogenization in 1 mL 
PCA (1%) and recentrifuged at 2000 g for 20 min. 
The two PCA extracts were then pooled and neu- 
tralized with a 1.5 M KOH/0.075 M HEPES solution 
in the presence of universal indicator pH 4-10. The 
resulting potassium perchlorate salt was then pel- 
leted by centrifugation (5 min at 2OOOg), resus- 
pended in 2 mL 0.5 mM EDTA/S mM Na2B40, and 
washed by centrifugation (5 min at 2000g). The 
supernatants from the two centrifugations were then 
pooled. A solution (10mL) containing 0.5 mM 
EDTA/S mM Na2B407 was then added to the pooled 
supernatant. The extracts (containing [3H]inositol 
and [3H]IPs) thus obtained were then applied to 
Dowex anion-exchange columns (1X8 formate form; 
height of resin: 4cm; diameter: 0.8cm). Aliquots 
(1.5 mL) were taken from the flow-through fractions 
and subjected to liquid scintillation counting. Each 
column was then washed once with 20 mL water. 
Glycerophosphoinositides (GPI) were eluted with 
20 mL 0.04 M ammonium formate/0.003 M sodium 
tetraborate. The IPs were eluted with 15 mL 0.8 M 
ammonium formate/O. 1 M formic acid. For both the 
GPI and IPs fractions, 4-mL aliquots were taken and 
radioassayed. Columns were regenerated twice with 
10 mL 2 M ammonium formate/O.l M formic acid 
and twice with 20 mL distilled water prior to re-use. 
Columns were discarded after five experiments. For 
liquid scintillation counting, 2.5 mL of Ready Gel 
scintillation fluid (Beckman Instruments Inc., 
Ireland) was added to the 1.5-mL aliquots obtained 
from the flow-through fractions while 6 and 7 mL of 
Ready Gel were added to the 4-mL aliquots con- 
taining the eluted GPI and IPs, respectively. 
Data calculation. Dose-response curves for agon- 
ists and antagonists were fitted using non-linear 
regression with experimental values weighted by the 
reciprocal of the variance, according to the logistic 
model described by De Lean et al. [15,16]. The 
computer programme used was the RS/l release 
3.0 program (BBN Software Product Corporation, 
Cambridge, MA, U.S.A.), run on a VAX 6210 
microcomputer. 
RESULTS 
Time course 
Carbachol (carb) enhanced IPi accumulation in 
the presence of 10 mM Li+ at 37” in the rat cochlea. 
This increase was exponential during the first 5 min 
and linear between 5 and 45 min of incubation (Fig. 
1 upper panel). Carb did not induce any IPi accumu- 
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Fig. 1. Time course of carbachol-induced formation of 
[‘H]IP,, [3H]IP2 and [3H]IP3 in rat cochleas. Experimental 
conditions are as described in Materials and Methods 
except that the cochleas were prelabelled with 500&i 
[3H]myo-inositol instead of 50 j&i for 75 min, washed five 
times, and then stimulated for different time periods with 
10 mM carbachol in the absence or in the presence of 
10 mM LiCl. In addition, the reaction was stopped using 
60 PL of a solution containing PCA (72%), EGTA (1 mM) 
and a nonradioactive mixture of inositol phosphates (2 m9/ 
mL) in order to inhibit the acidic phosphatases which 
catalyse the dephosphorylation of the various IPs metab- 
oiites. The elutions of the various metabolites from the 
Dowex 1X8 columns were performed as follows: twice with 
20mL of water to remove [3H]myo-inositol, once with 
15 mL of 0.04 M ammonium formate/0.003 M sodium tetra- 
borate for GPI, twice with 15mL of 0.15M ammonium 
formate/O.OOS M sodium tetraborate for IP,, twice with 
15 mL of 0.4 M ammonium formate/O.l M formic acid for 
IPs, twice with 15 mL of 0.8 M ammonium formate/O.l M 
formic acid for IP3 and once with 15 mL of 2 M ammonium 
formatejO.1 M formic acid for the other inositol phosphates. 
Results are means 2 SD of experiments done on at least 
six different co&leas (one IPs determination is performed 
for each individual cochlea). The basal IP,, IPs and IP3 
accumulation was not significantly affected by the presence 
of 10 mM Li+. 
lation in the absence of Li+ (Fig. 1 lower panel). 
Very little radioactivity was found in the IPz and IP3 
fractions and this was not affected by Li+. The basal 
levels of IPi, IPs and IP3 did not change with Li+. 
The results were expressed as the ratios of dpm 
contained in the various IP fractions to the dpm of 
incorporated inositol. Similar patterns were obtained 
when results were expressed as dpm per mg of pro- 
tein (data not shown). These preliminary experi- 
ments prompted us to measure the total IPs 
(containing about 98% of IPi and IPs) for a 20 min 
Muscarinic receptor and inositol phosphate in the rat cochlea 1915 
Table 1. Effect of neuroactive substances on the IPs formation in the rat cochlea 
Agonist 
Maximum Concentration 
Tested (M) 
Effect on IPs 
accumulation* 
Glutamate 
Quisqualate 
N-Methyl-D-aspartate 
Kainate 
Nicotine 
Carbachol 
Oxtremorine M 
Gamma-amino-butyric acid 
Glycine 
Noradrenaline 
5-Hydroxytryptamine 
Dopamine 
Substance P 
Neuropeptide Y 
Calcitonin gene related peptide 
Vasoactive intestinal peptide 
Arginine-vasopressin 
Cholecystokinin 
Met-enkephalin 
Leu-enkephalin 
Met-enkephalin-Arg6-Phe’ 
Oxytocin 
DAGOB 
DTLETlj 
DPLPET 
Potassium 
A 23187 
Monensin 
Valinomycin K 
Veratridine 
loo0 
1000 
1000 
1000 
10,ooo 
10,ooo 
loo0 
1OCO 
1000 
luoo 
loo0 
1000 
1 
1 96 2 13 
1 109 + 17 
87 f 12 
1 81 f 10 
1 115 2 29 
1 
1 
1 
1 
1 
60,ooo 
5 
50 
10 
100 + 26 
118 2 16 
101 f 21 
124 + 52 
79 f 29 
617 -c 66$ 
727 2 59$ 
102 * 23 
89 f 8 
114 +: 24 
135 + 23 
126 + 12 
113 + 26 
86 2 17 
100 f 18 
109 2 12 
99 f 17 
82 f 11 
72 + 3t 
91 f 34 
92 2 13 
96 & 23 
145 * 37 
79 + 12 
92 f 23 
* Results are expressed as percentages of control values. The mean control value is 
(47 2 13) x lo-’ dpm IPs/dpm [‘Hlinositol incorporated and the mean value of [3H]inositol 
incorporation is 41,130 & 12,170 dpm per cochlea. Results are expressed as means + SD 
of at least six individual determinations. The statistical significance of the agonist-stimulated 
IPs formation versus the control IPs values was calculated by two-tailed Student’s t-test. 
(t P < 0.01; $ P < 0.001). 
§ DAGO: (D-ala’, N methyl-phe4, glyol’) enkephalin. 
]I DTLET: (D-thr*, thr6) leu-enkephalin. 
1 DPLPE: (D-pen’, L-pen’) enkephalin. 
incubation period and to express the results as ratios 
(dpm IPs/dpm incorporated [3H]myo-inositol) for 
the following experiments. 
Effects of neuroactive substances on the IPs formation 
in the rat cochlea 
A large number of neuroactive substances, some 
of which are known to be present in the cochlea [S], 
ions and ionophores were screened for their ability 
to stimulate IPs formation in the cochlea (see Table 
1). With the exception of the muscarinic agonists 
carbachol and oxotremorine M, none of the sub- 
stances tested (nicotine included) had any significant 
stimulatory effect. 
Dose-response curve 
Carbachol and oxotremorine M induced IPs 
accumulation in a dose-dependent manner (Fig. 2). 
From the dose-response relationships, the ECs,, 
values were calculated, using a curve fitting pro- 
gramme indicated in Materials and Methods. They 
were 28 +- 20 PM and 87 k 19 PM for oxotremorine 
M and carbachol, respectively. A pre-analysis 
according to the logistic model proposed by Black et 
al. [17] shows that for the two agonists the slopes 
are approximately equal to 1. The E,,,, values for 
carbachol and for oxotremorine M are significantly 
different. These values expressed as percentages of 
the basal values are 570 f 60% and 799 + 93%, 
respectively. 
Effect of cholinergic antagonists on carbachol-elicited 
IPs accumulation 
A broad range of choline@ receptor antagonists 
were assessed for their ability to block the increased 
accumulation evoked by carbachol. The nicotinic 
antagonists D-tubocurarine and cu-bungarotoxin had 
no effect. On the contrary, muscarinic antagonists 
inhibited all the IPs formation induced by 10e3 M 
carbachol (Fig. 3). None of these choline@ antag- 
onists affected the basal IPs accumulation, except 
for a high concentration of methoctramine. At 
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Fig. 2. Concentration-response relationships of carbachol- 
and oxotremorine M-induced IPs formation in the rat coch- 
lea. Cochleas were labelled for 75 min with 50 &i [‘H)myo- 
inositol, and then washed four times to remove the excess 
of radioactive inositol. After preincubation with 10mM 
LiCl at 37” for 15 min, increasing concentrations of car- 
bachol or oxotremorine h4 were added and the cochleas 
were further incubated for 20min. The accumulation of 
(3H]IPs was measured by scintillation counting following 
Dowex 1X8 column chromatography. Results which are 
means f SE of experiments done on at least five different 
cochleas, show stimulation as a percentage of the basal 1,Ps 
formation. Basal IPs formation was 54,180 k 4913 dpm/mg 
protein (mean ? SE). 
10e3 M, methoctramine alone stimulates IPs accumu- 
lation (about 400% of basal value). The same level 
of stimulation is also obtained in the co-presence of 
10m3 M carbachol. The relative order of potency of 
the muscarinic antagonists were atropine > 4-DAMP 
S- pirenzepine > methoctramine = AF-DX 116. The 
IC, values which were calculated from the inhibition 
curves and were 0.007 & 0.007, 0.030 + 0.008, 
2.0 2 0.8, 33 2 7 and 63 2 42pM for atropine, 4- 
DAMP, pirenzepine, AF-DX 116 and methoc- 
tramine respectively. For each antagonist, pseudo- 
Hill numbers were determined (Table 2). In all cases 
they are not significantly different from 1. However, 
for methoctramine, this number is relatively low. 
DISCUSSION 
Our results indicate that among the neuroactive 
substances tested (Table l), some of which are 
known to occur in the cochlea [5], only choline@ 
agonists are able to stimulate the accumulation of 
IPs in the cochlea. Although nicotinic receptors seem 
to occur in the cochlea, (nicotine potentiates the 
submaximal effects of the stimulation of the crossed 
olivocochlear bundle [18]) their activation did not 
lead to IPs stimulation. Conversely, cholinergic 
50 
40 
34 
20 
IO 
o- 
. 
o- 
O- 
O- 
0- 
-Log [antagonisll (Ml 
Fig. 3. Elects of muscarinic antagonists on carbachol- 
induced IPs formation in the cochlea. Experimental con- 
ditions are as described in Materials and Methods. Chol- 
inergic antagonists (IO-’ M-10e3 M) were tested for their 
ability lo inhibit IPs formation induced by 1 mM carbachol. 
Results which are means 2 SE of experiments done on at 
least six different cochleas, show stimulation as a per- 
centage of the basal IPs formation. Antagonists pe.r se 
(atropine, 4-DAMP, methoctramine, pirenzepine and AF- 
DX 116) did not affect the basal IPs formation at the 
concentrations tested (except for high concentrations of 
methoctramine greater than 1O-4 M). D-Tubocurarine and 
a-bungarotoxin were without effect both on the basal and 
carbachol-stimulated IPs accumulation. 
Table 2. Calculated ICE and pseudo-Hill values for chol- 
inergic antagonists for inhibition of 1 mM carbachol- 
induced IPs formation in the rat cochlea 
Antagonist ‘%I (W) nH 
Atropine 0.007 c 0.007 0.83 2 0.47 
4-DAMP 0.03 2 0.008 0.94 + 0.15 
Pirenzepine 2.0 2 0.8 0.90 c 0.17 
AF-DX 116 33 + 7 0.91 t- 0.15 
Methoctramine 63 ? 42 0.79 2 0.49 
These values were calculated from the results presented 
in Fig. 3 as described in Materials and Methods. They 
are expressed as means -t SE of at least six individual 
determinations. 
agonists of the muscarinic receptor subtype (car- 
bachol and oxotremorine M) increase the metab- 
olism of IPs with a high apparent affinity. The fact 
that the E,,, values calculated for these two agonists 
are significantly different may indicate that carbachol 
is a partial agonist. The carbachol-stimulated IPs 
formation is not blocked by nicotinic antagonists 
such as D-tubocurarine and cu-bungarotoxin while 
it is inhibited by muscarinic antagonists (atropine, 
pirenzepine, 4-DAMP, methoctramine and AF-DX 
116). This clearly demonstrates that a muscarinic 
Muscarinic receptor and inositol phosphate in the rat cochlea 1917 
receptor is responsible for the IPs formation in the 
cochlea. Muscarinic receptors have recently been 
divided into five subtypes,* named ml, m2, m3, m4 
and m5 on the basis of molecular cloning experiments 
and the expression of this cloned muscarinic receptor 
in various cells [19-211. The ml and m2 receptor 
subtypes have also been cloned from porcine brain 
and heart [22-241. In order to determine which 
muscarinic receptor is implicated in the cholinergic- 
induced IPs formation in the cochlea, we have 
measured the inhibition, by various muscarinic 
antagonist of the IPs accumulation, induced by 1 mM 
carbachol. Although it would be better to determine 
Ki values from Schild plot analyses, we have only 
measured the lcso value for each antagonist in this 
paper (Table 2). The reasons for this are technical 
limitations such as the time taken for dissection, the 
time-restricted period for cochlear viability and the 
very small quantities of biological tissue present per 
cochlea. However, since the same concentration of 
carbachol was used for studying the antagonist inhi- 
bition, ICKY values thus determined will provide an 
approximate rank order of potency of the antag- 
onists. Subsequently, the subtype of receptor 
involved can be determined. The most widely used 
classification of muscarinic receptor subtypes was 
based on the relative affinities of the antagonists, 
pirenzepine and AF-DX 116 in particular [25-271. 
M1 receptors express a high apparent affinity toward 
pirenzepine and an intermediate affinity toward AF- 
DX 116 [26,28], whereas Mz receptors “cardiac 
type” (MZalpha) possess a low apparent affinity for 
pirenzepine and a high affinity for AF-DX 116 [26- 
28]. M3 receptors, previously known as the M2 
“glandular type” (MZbeta) present a low apparent 
affinity toward both pirenzepine and AF-DX 116 and 
a high affinity toward 4-DAMP [28,29]. Methoc- 
tramine was found to be as effective and selective as 
AF-DX 116 for the Mz receptor [30,31]. No specific 
antagonists, yet tested, allowed the distinction of 
m4 or m.5 from the rest of the muscarinic receptor 
subtypes [32]. By using a large variety of antagonists, 
it is possible to approximate the identification of the 
specific subtype of muscarinic receptor involved as 
demonstrated by a recent displacement-binding 
study carried out in CHO-Kl cells, in which cloned 
muscarinic receptors were expressed [32]. However, 
the pharmacological profile determined in this study 
cannot be easily applied to muscarinic receptor sub- 
type identification in other experimental models. 
Indeed, artificial receptor gene expression does not 
necessarily simulate exactly the expression occurring 
in vivo. Another indirect manner of characterization 
of receptor subtypes is the study of the biochemical 
* The nomenclature of the muscarinic receptor subtypes 
used in this paper is that recommended recently in the 
supplement of Trends in Pharmacological Sciences, 
December 1989, p. VII by the nomenclature committee of 
the fourth symposium on muscarinic subtypes. According 
to this nomenclature, the pharmacologically characterized 
receptor subtypes are known as M,, Mz and M,, while those 
characterized by molecular cloning techniques are named 
ml, m2, m3, m4 and m5. It is likely that the ml sequence 
corresponds to that of the M, receptor, m2 to the Mz 
receptor and m3 to the M3 receptor. 
responses triggered by their activation. Muscarinic 
receptors are coupled to a variety of second mess- 
enger systems involving adenylate cyclase and phos- 
phatidylinositol metabolism as well as to ion channels 
[20, 33-411. In fact, it was reported that M1 (ml), 
M3 (m3) and m5 receptors are coupled with the 
stimulation of phosphoinositides hydrolysis 
[20,26,29,35-37,39,40] whereas m2 and m4 are 
mainly linked to the inhibition of adenylate cyclase 
[36,38]. 
Our pharmacological results indicate that the 
muscarinic receptor subtypes involved in the IPs 
formation in the rat cochlea is probably a M3 recep- 
tor. In fact, pirenzepine has a low apparent affinity 
(IQ,, = 2 x 10m6 M) in inhibiting IPs synthesis which 
rules out the possibility of an interaction with the M1 
receptor. A similar low apparent affinity of piren- 
zepine was recently reported in receptor-binding 
studies to cochlear membranes using [3H]-l-qui- 
nuclidinylbenzylate [42]. We found a relatively low 
efficacy of AF-DX 116 or methoctramine for inhi- 
biting the carbachol-induced IPs accumulation in the 
rat cochlea (ICKY = 33 and 63 fi, respectively). This 
excludes the involvement of a M2 receptor subtype 
in this IPs response since these two antagonists 
present a high affinity for the M2 receptor subtype 
[26-301. The antagonist 4-DAMP inhibits the carb- 
achol-induced IPs response with a high apparent 
affinity, thus suggesting an action via the M3 receptor 
[29]. However, the potency of 4-DAMP has not been 
tested for its inhibitory action neither on the binding 
of muscarinic ligands to m4 or m5 receptor subtypes 
nor on the biochemical responses associated with 
the activation of these two latter receptor subtypes. 
Nevertheless, m4 receptors are rather shown to be 
coupled to adenylate cyclase inhibition than to IPs 
formation [36], suggesting that the response 
observed here, is probably not mediated by a m4 
muscarinic receptor. On the other hand, the 
expression of m5 receptors has not yet been observed 
in any tissue or cell line [32]. The paucity of phar- 
macological data concerning this receptor subtype, 
does not allow us to rule out the possibility of the 
existence of a m5 muscarinic receptor linked to inosi- 
to1 phosphate formation in the cochlea. If this is 
so, this will be the first indication of the natural 
expression of the m5 receptor gene in an organ. In 
fact, the antagonists used present about the same 
rank order of potencies in the binding studies on 
both the m3 and m5 receptors expressed in CHO- 
Kl cells: atropine ti methoctramine > pirenzepine 
% AF-DX 116 [32]. In our experiments, we found 
the following order of inhibitory action on carbachol- 
stimulated IPs formation: atropine * pirenzepine % 
AF-DX 116 = methoctramine. The apparent dis- 
crepancy concerning the inhibitory effect of methoc- 
tramine between the two sets of results may originate 
from the fact that methoctramine at concentrations 
greater than 10m4 M becomes an agonist in the coch- 
lea. This finding, which has also been reported in the 
rat cerebral cortex [43], may explain why the Hill 
number for methoctramine is not equal to 1. A 
low Hill number for methoctramine has also been 
obtained in [3H]-N-methylscopolamine displacement 
experiments on rat submaxillary gland membranes, 
thought to possess only M3 receptors [32]. Taken 
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together our results seem to indicate that cholinergic- 
induced IPs formation in the cochlea is probably 
mediated by the activation of a Ms muscarinic recep- 
tor. 
Our results also show that neither glutamate nor 
quisqualate stimulate IPs formation in the rat 
cochlea. Nevertheless several reports have shown 
that an excitatory amino acid is probably involved in 
the transmission between the IHCs and the primary 
auditory neurons [44] by activating a quisqualate 
receptor [1,45]. If so, the quisqualate receptor 
involved did not correspond to that linked to the 
phosphoinositide metabolism [46]. These facts 
reinforce the conclusion of our previous work [46] 
which indicate that two subtypes of quisqualate 
receptors do indeed exist in the central nervous 
system, one linked to ion channels, the other one to 
phosphoinositides metabolism. 
In conclusion, our data strongly suggest that 
among the known neuroactive substances found in 
the rat cochlea only muscarinic agonists mediate the 
stimulation of IPs turnover likely via a Ms receptor 
subtype. Acetylcholine is thought to be the main 
neurotransmitter between the medial efferent system 
and the OHCs [6], and inositol triphosphate causes 
the contraction of permeabilized OHCs in vitro 
[ll, 121. Thus, the activation of this second mess- 
enger pathway in the cochlea by acetylcholine via a 
M3 receptor may play a key role in the triggering or 
the control of slow OHCs motility, although the 
accurate cellular location of this second messenger 
remains to be elucidated. 
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